These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 25980499)

  • 1. Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells.
    Vouri M; An Q; Birt M; Pilkington GJ; Hafizi S
    Oncotarget; 2015 Jun; 6(18):16183-97. PubMed ID: 25980499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma.
    Sadahiro H; Kang KD; Gibson JT; Minata M; Yu H; Shi J; Chhipa R; Chen Z; Lu S; Simoni Y; Furuta T; Sabit H; Zhang S; Bastola S; Yamaguchi S; Alsheikh H; Komarova S; Wang J; Kim SH; Hambardzumyan D; Lu X; Newell EW; DasGupta B; Nakada M; Lee LJ; Nabors B; Norian LA; Nakano I
    Cancer Res; 2018 Jun; 78(11):3002-3013. PubMed ID: 29531161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo.
    Onken J; Torka R; Korsing S; Radke J; Krementeskaia I; Nieminen M; Bai X; Ullrich A; Heppner F; Vajkoczy P
    Oncotarget; 2016 Mar; 7(9):9876-89. PubMed ID: 26848524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma.
    Fleuren ED; Hillebrandt-Roeffen MH; Flucke UE; Te Loo DM; Boerman OC; van der Graaf WT; Versleijen-Jonkers YM
    Oncotarget; 2014 Dec; 5(24):12753-68. PubMed ID: 25528764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression.
    von Mässenhausen A; Brägelmann J; Billig H; Thewes B; Queisser A; Vogel W; Kristiansen G; Schröck A; Bootz F; Brossart P; Kirfel J; Perner S
    Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28025482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.
    Hector A; Montgomery EA; Karikari C; Canto M; Dunbar KB; Wang JS; Feldmann G; Hong SM; Haffner MC; Meeker AK; Holland SJ; Yu J; Heckrodt TJ; Zhang J; Ding P; Goff D; Singh R; Roa JC; Marimuthu A; Riggins GJ; Eshleman JR; Nelkin BD; Pandey A; Maitra A
    Cancer Biol Ther; 2010 Nov; 10(10):1009-18. PubMed ID: 20818175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma.
    Bae CA; Ham IH; Oh HJ; Lee D; Woo J; Son SY; Yoon JH; Lorens JB; Brekken RA; Kim TM; Han SU; Park WS; Hur H
    Gastric Cancer; 2020 Sep; 23(5):824-836. PubMed ID: 32239298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target.
    Tutusaus A; de Gregorio E; Cucarull B; Cristóbal H; Aresté C; Graupera I; Coll M; Colell A; Gausdal G; Lorens JB; García de Frutos P; Morales A; Marí M
    Cell Mol Gastroenterol Hepatol; 2020; 9(3):349-368. PubMed ID: 31689560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted inhibition of Axl receptor tyrosine kinase ameliorates anti-GBM-induced lupus-like nephritis.
    Zhen Y; Lee IJ; Finkelman FD; Shao WH
    J Autoimmun; 2018 Sep; 93():37-44. PubMed ID: 29895432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galectin-3 Stimulates Tyro3 Receptor Tyrosine Kinase and Erk Signalling, Cell Survival and Migration in Human Cancer Cells.
    Al Kafri N; Hafizi S
    Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32664510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model.
    Chen TJ; Mydel P; Benedyk-Machaczka M; Kamińska M; Kalucka U; Blø M; Furriol J; Gausdal G; Lorens J; Osman T; Marti HP
    Physiol Rep; 2021 Dec; 9(23):e15140. PubMed ID: 34877810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.
    Antony J; Tan TZ; Kelly Z; Low J; Choolani M; Recchi C; Gabra H; Thiery JP; Huang RY
    Sci Signal; 2016 Oct; 9(448):ra97. PubMed ID: 27703030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer.
    Palisoul ML; Quinn JM; Schepers E; Hagemann IS; Guo L; Reger K; Hagemann AR; McCourt CK; Thaker PH; Powell MA; Mutch DG; Fuh KC
    Mol Cancer Ther; 2017 Dec; 16(12):2881-2891. PubMed ID: 28904132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of the Receptor Tyrosine Kinase AXL in Response to Therapy and Its Role in Therapy Resistance in Glioblastoma.
    Scherschinski L; Prem M; Kremenetskaia I; Tinhofer I; Vajkoczy P; Karbe AG; Onken JS
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival.
    Vajkoczy P; Knyazev P; Kunkel A; Capelle HH; Behrndt S; von Tengg-Kobligk H; Kiessling F; Eichelsbacher U; Essig M; Read TA; Erber R; Ullrich A
    Proc Natl Acad Sci U S A; 2006 Apr; 103(15):5799-804. PubMed ID: 16585512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer.
    Danielli SG; Wurth J; Morice S; Kisele S; Surdez D; Delattre O; Bode PK; Wachtel M; Schäfer BW
    Mol Cancer Ther; 2024 Jun; 23(6):864-876. PubMed ID: 38471796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bemcentinib and Gilteritinib Inhibit Cell Growth and Impair the Endo-Lysosomal and Autophagy Systems in an AXL-Independent Manner.
    Zdżalik-Bielecka D; Kozik K; Poświata A; Jastrzębski K; Jakubik M; Miączyńska M
    Mol Cancer Res; 2022 Mar; 20(3):446-455. PubMed ID: 34782372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.
    Giles KM; Kalinowski FC; Candy PA; Epis MR; Zhang PM; Redfern AD; Stuart LM; Goodall GJ; Leedman PJ
    Mol Cancer Ther; 2013 Nov; 12(11):2541-58. PubMed ID: 24026012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma.
    Xu F; Li H; Sun Y
    Biochem Biophys Res Commun; 2014 Nov; 454(4):566-71. PubMed ID: 25450694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corosolic Acid Attenuates the Invasiveness of Glioblastoma Cells by Promoting CHIP-Mediated AXL Degradation and Inhibiting GAS6/AXL/JAK Axis.
    Sun LW; Kao SH; Yang SF; Jhang SW; Lin YC; Chen CM; Hsieh YH
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.